{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-24-000168","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2024-08-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.231997+00:00","generated_at":"2026-05-31T13:58:44.220369+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Denali Q2 net loss $99M; FDA open to accelerated approval for DNL310; regains ATV:Abeta rights","bullets":["Net loss $99.0M in Q2 2024 vs $183.4M net income in Q2 2023; no collaboration revenue versus $294.1M last year.","Cash and marketable securities $1.35B as of June 30, 2024.","FDA CDER open to discussing accelerated approval for DNL310 (MPS II) using CSF HS as surrogate biomarker.","Biogen terminated ATV:Abeta license; Denali regains all rights; decision not related to efficacy or safety.","DNL126 (MPS IIIA) selected for FDA START pilot program; Phase 1/2 data expected by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-24-000168","json":"https://secwatch.observer/filing/0001714899-24-000168.json","markdown":"https://secwatch.observer/filing/0001714899-24-000168.md","text":"https://secwatch.observer/filing/0001714899-24-000168.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000168/0001714899-24-000168-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489924000168/dnli-20240801.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T13:58:44.220369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}